Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORTAL: Pola-Glofit-Obinutuzumab in LBCL
NCT06071871Phase 2Recruiting
- Sponsor
- University College London
- Start
- Aug 2024
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by University College London. Started Aug 2024; status: recruiting.
02
Drugs
glofitamabpolatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06071871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06071871.